Investor Presentaiton slide image

Investor Presentaiton

Investor presentation ADA 2019 Slide 21 Innovation and convenience for patients on basal insulin with once-weekly insulin LAI287 Rationale for a once-weekly insulin Provide an efficacious, safe and convenient once-weekly alternative to once-daily basal insulin for patients with type 2 diabetes LAI287 phase 2 programme 2019 H1 | 2019 H2 2020 H1 180 Fewer injections Lower treatment burden could lead to higher compliance T2D, insulin naïve + OAD vs glargine ~250 patients, 26 weeks T2D, insulin naïve Different titrations vs glargine ~200 patients, 16 weeks T2D, + OAD With and without loading dose vs glargine ~150 patients, 16 weeks Expected phase 2 programme completion: H1 2020 T2D: type 2 diabetes; OAD: oral antidiabetes drugs novo nordisk
View entire presentation